ReviewAnemia2026
Systematic Review on Plant-Based Therapies for the Management of Sickle Cell Anaemia.
Review in Anemia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Sickle cell anaemia (SCA) is a hereditary haemoglobin disorder that continues to pose a significant public health burden worldwide. This systematic review aimed to synthesise evidence on plant-derived therapies investigated for their antisickling, antioxidant and membrane-stabilising effects in the management of SCA. Methods: A systematic search of PubMed, Scopus and Web of Science was performed according to PRISMA 2020 guidelines to identify studies (2010-2025) evaluating plant-based interventions for SCA. Results: Thirty-four studies published between 2010 and 2025 were included, with the majority (58.8%) published between 2018 and 2025, while 20.6% were published between 2010 and 2012. Most studies originated from Africa (58.8%), particularly Nigeria and the Democratic Republic of the Congo, followed by Asia (26.5%). Conclusion: The evidence demonstrates that plant-derived extracts and phytochemicals possess significant antisickling, antioxidant and membrane-protective activity, supporting their potential as adjunct therapies for SCA. Nonetheless, standardisation of experimental protocols, toxicological evaluation and clinical trials are essential to advance towards clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.